智通财经APP讯,德琪医药-B(06996)发布公告,中国国家药品监督管理局(国家药监局)已批准用于评估 ATG-022(CLDN18.2抗体药物偶联物ADC)联 合 MSD (Merck & Co., Inc., Rahway, NJ, USA)的抗PD 1疗法KEYTRUDA®(帕博利珠单抗)以及ATG-022联合帕博利珠单抗及化疗的Ib/II期CLINCH-2研究的研究性新药(IND)申请。
智通财经APP讯,德琪医药-B(06996)发布公告,中国国家药品监督管理局(国家药监局)已批准用于评估 ATG-022(CLDN18.2抗体药物偶联物ADC)联 合 MSD (Merck & Co., Inc., Rahway, NJ, USA)的抗PD 1疗法KEYTRUDA®(帕博利珠单抗)以及ATG-022联合帕博利珠单抗及化疗的Ib/II期CLINCH-2研究的研究性新药(IND)申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.